BofA raised the firm’s price target on Alnylam (ALNY) to $325 from $302 and keeps a Buy rating on the shares. Amvuttra was approved in the U.S.

The profitability screen requires that the sum of a company’s GAAP earnings over the past four quarters be positive as well as the most recent quarter. The screen imparts a slight quality tilt ...